Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Marsh

Showing results (401-410 of 654) with videos related to

Pageof 66
Sort By:
Transplantation|October 15, 1998
Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung functionA F Pierre, A M Xavier, M Liu, et al.
Journal of Medicinal Chemistry|June 13, 2003
Synthesis and complement inhibitory activity of B/C/D-ring analogues of the fungal metabolite 6,7-diformyl-3',4',4a',5',6',7',8',8a'-octahydro-4,6',7'-trihydroxy- 2',5',5',8a'-tetramethylspiro[1'(2'H)-naphthalene-2(3H)-benzofuran]Barton J Bradbury, Piotr Bartyzel, Teodoro S Kaufman, et al.
British Journal of Haematology|October 1, 1994
Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine ('Ecstasy')J C Marsh, Z H Abboudi, F M Gibson, et al.
Journal of Substance Abuse Treatment|June 7, 2021
A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use researchKirsten Marchand, Heather Palis, Daphne Guh, et al.
Journal of Addiction Medicine|February 8, 2020
Physician Communication in Injectable Opioid Agonist Treatment: Collecting Patient Ratings With the Communication Assessment ToolHeather Palis, Kirsten Marchand, Scott Beaumont, et al.
Journal of Medicinal Chemistry|November 2, 2001
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonistsH S Jae, M Winn, T W von Geldern, et al.
Cancer|January 15, 1980
Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non-lymphocytic leukemia in adultsR T Skeel, W Costello, J M Bennett, et al.
The Journal of Urology|February 1, 1992
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostateK Mellon, S Thompson, R G Charlton, et al.
Biochemical and Biophysical Research Communications|June 6, 1995
Potent inhibitors of the HIV-1 protease with good oral bioavailabilitiesH L Sham, C Zhao, K C Marsh, et al.
Lancet (London, England)|July 16, 1994
Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic AnaemiaJ C Marsh, G Socie, H Schrezenmeier, et al.
Pageof 66

Showing results (401-410 of 654) with videos related to

Sort By:
Pageof 66
Transplantation|October 15, 1998
Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung functionA F Pierre, A M Xavier, M Liu, et al.
Journal of Medicinal Chemistry|June 13, 2003
Synthesis and complement inhibitory activity of B/C/D-ring analogues of the fungal metabolite 6,7-diformyl-3',4',4a',5',6',7',8',8a'-octahydro-4,6',7'-trihydroxy- 2',5',5',8a'-tetramethylspiro[1'(2'H)-naphthalene-2(3H)-benzofuran]Barton J Bradbury, Piotr Bartyzel, Teodoro S Kaufman, et al.
British Journal of Haematology|October 1, 1994
Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine ('Ecstasy')J C Marsh, Z H Abboudi, F M Gibson, et al.
Journal of Substance Abuse Treatment|June 7, 2021
A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use researchKirsten Marchand, Heather Palis, Daphne Guh, et al.
Journal of Addiction Medicine|February 8, 2020
Physician Communication in Injectable Opioid Agonist Treatment: Collecting Patient Ratings With the Communication Assessment ToolHeather Palis, Kirsten Marchand, Scott Beaumont, et al.
Journal of Medicinal Chemistry|November 2, 2001
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonistsH S Jae, M Winn, T W von Geldern, et al.
Cancer|January 15, 1980
Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non-lymphocytic leukemia in adultsR T Skeel, W Costello, J M Bennett, et al.
The Journal of Urology|February 1, 1992
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostateK Mellon, S Thompson, R G Charlton, et al.
Biochemical and Biophysical Research Communications|June 6, 1995
Potent inhibitors of the HIV-1 protease with good oral bioavailabilitiesH L Sham, C Zhao, K C Marsh, et al.
Lancet (London, England)|July 16, 1994
Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic AnaemiaJ C Marsh, G Socie, H Schrezenmeier, et al.
Pageof 66